Publications (original articles or review articles) published in 2023 from OUS - Department of Oncology
19 publications found
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
PLoS One, 18 (2), e0281166
DOI 10.1371/journal.pone.0281166, PubMed 36730349
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor
JCO Precis Oncol, 7, e2200351
DOI 10.1200/PO.22.00351, PubMed 36724411
A study of modifiable factors associated with health-related quality of life in long-term cervical cancer survivors
Acta Obstet Gynecol Scand, 102 (2), 218-225
DOI 10.1111/aogs.14490, PubMed 36683549
Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment
Acta Oncol, 1-9 (in press)
DOI 10.1080/0284186X.2023.2168215, PubMed 36715320
An HPV-Vaccinated Patient With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
JAMA Otolaryngol Head Neck Surg, 149 (1), 92-94
DOI 10.1001/jamaoto.2022.3762, PubMed 36416857
[Not Available]
Tidsskr Nor Laegeforen, 143 (1)
DOI 10.4045/tidsskr.22.0668, PubMed 36655956
Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients
J Clin Invest (in press)
DOI 10.1172/JCI164809, PubMed 36719749
Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
Front Med (Lausanne), 9, 1051825
DOI 10.3389/fmed.2022.1051825, PubMed 36733936
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
Int J Cancer (in press)
DOI 10.1002/ijc.34448, PubMed 36715014
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086
2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
Front Neuroinform, 16, 1056068
DOI 10.3389/fninf.2022.1056068, PubMed 36743439
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Br J Cancer (in press)
DOI 10.1038/s41416-022-02133-6, PubMed 36624219
Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy
J Clin Oncol, JCO2201456 (in press)
DOI 10.1200/JCO.22.01456, PubMed 36626694
[Not Available]
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0314, PubMed 36718891
Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study
J Clin Oncol, JCO2201096 (in press)
DOI 10.1200/JCO.22.01096, PubMed 36599120
New centres to carry out more clinical trials in Norway
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.22.0722, PubMed 36718905
Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
Radiother Oncol, 109501 (in press)
DOI 10.1016/j.radonc.2023.109501, PubMed 36720348
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Crit Care, 27 (1), 9
DOI 10.1186/s13054-022-04205-8, PubMed 36627655
Overall severe morbidity after chemo-radiotherapy and MRI guided adaptive brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study
Int J Radiat Oncol Biol Phys (in press)
DOI 10.1016/j.ijrobp.2023.01.002, PubMed 36641039